remaining two segments, Integrated Oxides & Derivatives and Specialty Chemicals are expected to resume their earnings from unplanned shutdowns, except IPA which we believe will recover over the next 12-18
Total Installed Capacity (T) Earnings in $M Capex in $M Olympus Cost Transformation Program Corporate and all business segments 2020-2023 n/a EBITDA ~350 ~500 Corpus Christi PET/PTA Integrated PET 2022
Installed Capacity (KT) Earnings & Returns Capex in $M Olympus Cost Transformation Program Corporate and all business segments 2020-2023 n/a EBITDA ~$350M ~400 Corpus Christi PET/PTA Integrated PET 2023 PET
USA PX and global PIA business as feedstock costs have come down. • Integrated oxide and derivatives business has seen significant growth in volumes and earnings primarily driven by the first time
production volume and higher overall earnings as assets acquired in 2018 and the consolidations of 2018/19 were successfully integrated. These include acquisitions of PTA Portugal, PET (Egypt and Brazil), and
benefitted from higher production volume and higher overall earnings as assets acquired in 2018 and the consolidations of 2018/19 were successfully integrated. These include acquisitions of PTA Portugal, PET
debt to equity (times) 1.17 1.24 Debts with fixed interest % 67% 70% Credit Rating by TRIS AA- AA- 1 Net debt after debt for capex and investments in progress that are not generating revenue and earnings
after debt for capex and investments in progress that are not generating revenue and earnings as on date given. Figure 1 :Repayment Schedule of Long Term Debt 1 Includes various projects underway which
profit for 6M2019 was THB 1,136. 61 million, increased by THB 37. 76 million or 3. 44% up as compared to 6M2018 mainly from higher revenue from sales. Other Income The consolidated other income in 2Q2019
1,850. 25 million, increased by THB 46. 79 million or 2. 59% up as compared to 9M2018 mainly from higher revenue from sales. Other Income The consolidated other income in 3Q2019 was THB 65.26 million